

April W Armstrong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5694455/publications.pdf>

Version: 2024-02-01

206
papers

13,342
citations

31902

53
h-index

26548

107
g-index

220
all docs

220
docs citations

220
times ranked

10201
citing authors

#	ARTICLE	IF	CITATIONS
1	Reply to: "Comment on "Dermatologists in social media: A study on top influencers, posts, and user engagement"™". Journal of the American Academy of Dermatology, 2022, 86, e51.	0.6	6
2	Mental health outcomes and their association to race and ethnicity in acne patients: A population-based study. Journal of the American Academy of Dermatology, 2022, 87, 140-142.	0.6	3
3	Opiate use in dermatology: A population-based study using the National Ambulatory Medical Care Survey in the United States. Journal of the American Academy of Dermatology, 2022, 87, 174-176.	0.6	0
4	Chronic spontaneous urticaria in the United States: patient characteristics and treatment patterns. International Journal of Dermatology, 2022, 61, .	0.5	0
5	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. Journal of Dermatological Treatment, 2022, 33, 2317-2324.	1.1	17
6	Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States. Journal of the American Academy of Dermatology, 2022, 86, 748-757.	0.6	20
7	International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. Dermatology, 2022, 238, 430-437.	0.9	4
8	Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis. American Journal of Clinical Dermatology, 2022, 23, 1-11.	3.3	15
9	Defining Psoriasis Remission Based on Histopathologic and Molecular Criteria: A Systematic Literature Review. Journal of Investigative Dermatology, 2022, 142, 2026-2029.e4.	0.3	0
10	Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease. JAMA Dermatology, 2022, 158, 252.	2.0	15
11	Re-Classification of Psoriasis Severity: Perspectives and Controversy. Journal of Psoriasis and Psoriatic Arthritis, 2022, 7, 7-8.	0.3	0
12	Misconceptions of photoprotection in skin of color. Journal of the American Academy of Dermatology, 2022, 86, S9-S17.	0.6	20
13	Photoprotection for skin of all color: Consensus and clinical guidance from an expert panel. Journal of the American Academy of Dermatology, 2022, 86, S1-S8.	0.6	20
14	Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis. Dermatology and Therapy, 2022, 12, 727-740.	1.4	9
15	A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17. Dermatology and Therapy, 2022, 12, 787-800.	1.4	6
16	Economic Burden of Chronic Hand Eczema: A Review. American Journal of Clinical Dermatology, 2022, 23, 287-300.	3.3	11
17	Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey. Dermatology and Therapy, 2022, 12, 1055-1064.	1.4	13
18	Long-Term Benefit"Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. Dermatology and Therapy, 2022, 12, 167-184.	1.4	22

#	ARTICLE	IF	CITATIONS
19	Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis. <i>Dermatology and Therapy</i> , 2022, 12, 1181-1196.	1.4	24
20	Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey. <i>Advances in Therapy</i> , 2022, 39, 2657-2667.	1.3	7
21	2021 GRAPPA Trainee Symposium: A Summary of Oral and Poster Presentations. <i>Journal of Rheumatology</i> , 2022, , jrheum.211318.	1.0	0
22	Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment. <i>Dermatology and Therapy</i> , 2022, 12, 195-202.	1.4	4
23	The psoriasis glycome: differential expression of cholesterol particle glycans and IgA glycans linked to disease severity. <i>Journal of Investigative Dermatology</i> , 2022, , .	0.3	0
24	2021 GRAPPA Meet the Experts Session: A Summary of Presentations.. <i>Journal of Rheumatology</i> , 2022, , .	1.0	0
25	Development of a core outcome set for basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 573-581.	0.6	5
26	Achievement of the National Psoriasis Foundation treatment targets with ixekizumab: Pooled analyses from 4 clinical studies. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 330-336.	0.6	2
27	Response to Letter to the Editor commenting on: "Dermatologists in social media: A study on top influencers, posts, and user engagement" <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e165.	0.6	0
28	Association between atopic dermatitis and conjunctivitis in adults: a population-based study in the United States. <i>Journal of Dermatological Treatment</i> , 2021, 32, 455-459.	1.1	11
29	Response to Letter to the Editor "Reply to "Dermatologists in Social Media: A Study on Top Influencers, Posts, and User Engagement" <i>Journal of the American Academy of Dermatology</i> , 2021, , .	0.6	2
30	Economics of Tele dermatology "Does the Math Add Up?. <i>JAMA Dermatology</i> , 2021, 157, 27.	2.0	5
31	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , 2021, 397, 487-498.	6.3	139
32	Words matter: a randomized controlled study evaluating the impact of decision framing on treatment preferences in adults with psoriasis and psoriatic arthritis. <i>British Journal of Dermatology</i> , 2021, 184, 971-973.	1.4	3
33	Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. <i>Dermatology and Therapy</i> , 2021, 11, 885-905.	1.4	40
34	Pemphigus and bullous pemphigoid in the United States: a 21-year analysis of patient characteristics, treatment patterns, and comorbidities. <i>Journal of Dermatological Treatment</i> , 2021, , 1-3.	1.1	0
35	GRAPPA Trainee Symposium 2020: A Summary of Oral and Poster Presentations. <i>Journal of Rheumatology</i> , 2021, , jrheum.201670.	1.0	1
36	Childhood atopic dermatitis: outpatient visit trends, demographics, and topical agents in the United States, 1995-2015. <i>International Journal of Dermatology</i> , 2021, 60, e423-e424.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Psoriasis. <i>Lancet, The</i> , 2021, 397, 1301-1315.	6.3	792
38	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2â€”Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1254-1268.	0.6	88
39	Non-Medical Switching Impact on Patients and Providers â€” Psoriatic Disease Community Taking a Stand. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 126-127.	0.3	0
40	Anogenital warts and relationship to child sexual abuse: Systematic review and metaâ€”analysis. <i>Pediatric Dermatology</i> , 2021, 38, 842-850.	0.5	5
41	Mental health outcomes in White patients versus patients with skin of color with psoriasis. <i>Dermatology Online Journal</i> , 2021, 27, .	0.2	3
42	Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24â€”Months of Follow-Up: Results from US Dermatology Electronic Medical Records. <i>Dermatology and Therapy</i> , 2021, 11, 1733-1749.	1.4	5
43	Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 572-581.	0.6	36
44	Differences in acne therapy prescribing patterns between dermatologists and pediatricians: A populationâ€”based study. <i>Pediatric Dermatology</i> , 2021, 38, 1150-1156.	0.5	1
45	A Blueprint for the Conduct of Large, Multisite Trials in Telemedicine. <i>Journal of Medical Internet Research</i> , 2021, 23, e29511.	2.1	1
46	Trichotillomania in the United States: An epidemiologic study of patient characteristics, comorbidities, and treatment patterns. <i>Dermatology Online Journal</i> , 2021, 27, .	0.2	0
47	Chronic spontaneous urticaria: a 16-year analysis of pediatric patient demographics, treatment patterns, and comorbidities. <i>Dermatology Online Journal</i> , 2021, 27, .	0.2	1
48	Validation of Patient-Reported Psoriasis Diagnosis from a Global Online Research Network. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2539-2541.	0.3	0
49	Topical opioid use in dermatologic disease: A systematic review. <i>Dermatologic Therapy</i> , 2021, 34, e15150.	0.8	1
50	Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2021, 11, 2147-2157.	1.4	4
51	Bullous Dermatoses and Depression. <i>JAMA Dermatology</i> , 2021, 157, 1487.	2.0	5
52	Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 2219-2229.	13.9	93
53	Are we contributing to the opioid epidemic? A systematic review on systemic opioid use in dermatology. <i>International Journal of Dermatology</i> , 2021, , .	0.5	0
54	Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses. <i>Journal of Dermatological Treatment</i> , 2020, 31, 452-459.	1.1	4

#	ARTICLE	IF	CITATIONS
55	Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. <i>Journal of Dermatological Treatment</i> , 2020, 31, 606-614.	1.1	72
56	An association between hidradenitis suppurativa and <scp>HIV</scp>. <i>British Journal of Dermatology</i> , 2020, 182, 490-491.	1.4	4
57	Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. <i>Journal of Dermatological Treatment</i> , 2020, 31, 617-623.	1.1	10
58	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 936-945.	0.6	71
59	Addressing Hypertension in Patients With Psoriasis: Review and Recommendations. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 129-138.	0.3	1
60	Strategies to maximize clinical efficiency while maintaining patient safety during the COVID-19 pandemic: an interview-based study from private practice dermatologists. <i>Journal of Dermatological Treatment</i> , 2020, , 1-4.	1.1	8
61	Language proficiency and biologics access: a population study of psoriasis patients in the United States. <i>Journal of Dermatological Treatment</i> , 2020, , 1-5.	1.1	2
62	Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 881-890.	3.3	24
63	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1704-1716.	0.6	43
64	Pathophysiology, Clinical Presentation, and Treatment of Psoriasis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1945.	3.8	953
65	Association Between the Mental Health of Patients With Psoriasis and Their Satisfaction With Physicians. <i>JAMA Dermatology</i> , 2020, 156, 754.	2.0	4
66	Wound eversion versus planar closure for wounds on the face or neck: A randomized split-wound comparative effectiveness trial. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1439-1440.	0.6	3
67	Dermatologists in social media: A study on top influencers, posts, and user engagement. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1452-1455.	0.6	42
68	Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 411.	2.0	241
69	A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). <i>Journal of Investigative Dermatology</i> , 2020, 140, 1784-1793.e2.	0.3	61
70	Comparison of Biologics and Oral Treatments for Plaque Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 258.	2.0	169
71	Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic. <i>Dermatology Online Journal</i> , 2020, 26, .	0.2	4
72	Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 923-930.	0.6	11

#	ARTICLE	IF	CITATIONS
73	Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. <i>Lancet, The</i> , 2019, 394, 831-839.	6.3	250
74	Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry. <i>RMD Open</i> , 2019, 5, e000867.	1.8	21
75	Dermal suture only versus layered closure: A randomized, split wound comparative effectiveness trial. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1346-1352.	0.6	10
76	Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis. <i>PLoS ONE</i> , 2019, 14, e0210517.	1.1	22
77	Comparison of physical and mental functioning among moderate-to-severe psoriasis patients on biologic versus oral therapy. <i>Archives of Dermatological Research</i> , 2019, 311, 453-460.	1.1	2
78	Exploring Mental Disorders in Patients With Skin Diseases. <i>JAMA Dermatology</i> , 2019, 155, 660.	2.0	1
79	Evaluating Costs of Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 133-142.	0.3	2
80	Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. <i>British Journal of Dermatology</i> , 2019, 181, 967-975.	1.4	34
81	Economic burden of cutaneous infections in children and adults with atopic dermatitis. <i>Pediatric Dermatology</i> , 2019, 36, 303-310.	0.5	14
82	Online Care Versus In-Person Care for Improving Quality of Life in Psoriasis: A Randomized Controlled Equivalency Trial. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1037-1044.	0.3	37
83	A provider global assessment quality measure for clinical practice for inflammatory skin disorders. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 823-828.	0.6	7
84	Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30 Phase III VOYAGE 1 and VOYAGE 2 Studies. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 155-164.	3.3	37
85	Quality of life among dermatology patients: a systematic review of investigations using qualitative methods. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 72-78.	0.8	9
86	Suicidality among psoriasis patients: a critical evidence synthesis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 56-63.	0.8	7
87	Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2019, 30, 454-460.	1.1	15
88	Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1093-1104.	1.6	55
89	Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized <scp>VOYAGE</scp> 1 and <scp>VOYAGE</scp> 2 studies. <i>British Journal of Dermatology</i> , 2019, 180, 1039-1049.	1.4	57
90	Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial. <i>Journal of Dermatological Treatment</i> , 2019, 30, 27-34.	1.1	20

#	ARTICLE	IF	CITATIONS
91	Report of the Skin Research Workgroups from the GRAPPA 2018 Annual Meeting. <i>Journal of Rheumatology</i> , 2019, 95, 28-32.	1.0	2
92	Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. <i>Current Medical Research and Opinion</i> , 2018, 34, 1325-1333.	0.9	27
93	Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. <i>Archives of Dermatological Research</i> , 2018, 310, 271-319.	1.1	84
94	Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 383-394.	0.6	69
95	Hidradenitis suppurativa and diabetes mellitus: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 395-402.	0.6	36
96	Are patients comprehending? A critical assessment of online patient educational materials. <i>Journal of Dermatological Treatment</i> , 2018, 29, 295-299.	1.1	14
97	Psoriasis in solid organ transplant patients: best practice recommendations from The Medical Board of the National Psoriasis Foundation. <i>Journal of Dermatological Treatment</i> , 2018, 29, 329-333.	1.1	13
98	Characteristics of Medical Liability Claims Against Dermatologists From 1991 Through 2015. <i>JAMA Dermatology</i> , 2018, 154, 160.	2.0	20
99	Using qualitative methods to understand factors contributing to patient satisfaction among dermatology patients: a systematic review. <i>Journal of Dermatological Treatment</i> , 2018, 29, 290-294.	1.1	10
100	Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>American Journal of Clinical Dermatology</i> , 2018, 19, 879-886.	3.3	20
101	Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2018, 234, 112-119.	0.9	1
102	Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007394.	1.3	115
103	Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization. <i>BMC Dermatology</i> , 2018, 18, 4.	2.1	24
104	Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis. <i>Dermatology</i> , 2018, 234, 157-165.	0.9	10
105	Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials. <i>JAMA Dermatology</i> , 2018, 154, 1137.	2.0	41
106	Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation. <i>JAMA Dermatology</i> , 2018, 154, 934.	2.0	112
107	Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 40-43.	1.0	2
108	Oral small molecules for psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 163-166.	1.6	2

#	ARTICLE	IF	CITATIONS
109	Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. <i>Rheumatology International</i> , 2017, 37, 97-105.	1.5	48
110	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 418-431.	0.6	554
111	Development and psychometric evaluation of the self-assessment of psoriasis symptoms (SAPS) – clinical trial and the SAPS – real world patient-reported outcomes. <i>Journal of Dermatological Treatment</i> , 2017, 28, 505-514.	1.1	8
112	Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 701-702.	1.0	9
113	Benchmarking Care in Psoriatic Arthritis – The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 674-678.	1.0	18
114	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 290-298.	0.6	137
115	Antibiotic Resistance in Acne Treatment. <i>JAMA Dermatology</i> , 2017, 153, 810.	2.0	54
116	Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States. <i>Clinical Drug Investigation</i> , 2017, 37, 493-501.	1.1	15
117	Psoriasis and suicidality: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 425-440.e2.	0.6	117
118	Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 200-205.	1.1	12
119	Association of Touch Avoidance with Disease Severity and Quality of Life in Psoriasis Patients. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017, 2, 57-63.	0.3	2
120	An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. <i>PLoS ONE</i> , 2017, 12, e0181039.	1.1	79
121	Effect of a Pre-Treatment Educational Video in Improving Patient Satisfaction with 5-Fluorouracil Treatment for Actinic Keratoses: A Randomized Controlled Trial. <i>Dermatology and Therapy</i> , 2016, 6, 675-681.	1.4	6
122	Perceptions of Aesthetic Outcome of Linear vs Multiple Z-Plasty Scars in a National Survey. <i>JAMA Facial Plastic Surgery</i> , 2016, 18, 263-267.	2.2	10
123	Screening Recommendations for Hepatitis B Virus Infection. <i>JAMA Dermatology</i> , 2016, 152, 565.	2.0	0
124	International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update. <i>Journal of Rheumatology</i> , 2016, 43, 959-960.	1.0	8
125	Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 740-746.	0.6	20
126	Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. <i>New England Journal of Medicine</i> , 2016, 375, 422-434.	13.9	530

#	ARTICLE	IF	CITATIONS
127	From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 798-805.e7.	0.6	28
128	Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 906-917.	0.6	45
129	A Clinician's Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 329-336.	3.3	39
130	Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 691-699.	3.3	25
131	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	2.9	726
132	Managing Patients With Psoriasis in the Busy Clinic. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 196-206.	0.6	16
133	Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 79-86.	3.3	21
134	US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 87-97.	3.3	173
135	Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2016, 152, 661.	2.0	46
136	RAC1 activation drives pathologic interactions between the epidermis and immune cells. <i>Journal of Clinical Investigation</i> , 2016, 126, 2661-2677.	3.9	48
137	Relationship between psoriasis and metabolic syndrome: a systematic review. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2016, 151, 663-677.	0.8	31
138	Does class attendance matter? Results from a second-year medical school dermatology cohort study. <i>International Journal of Dermatology</i> , 2015, 54, 807-816.	0.5	51
139	Effect of tonsillectomy on psoriasis: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 261-275.	0.6	56
140	The global burden of psoriatic skin disease. <i>British Journal of Dermatology</i> , 2015, 172, 1665-1668.	1.4	64
141	Patient-Centered Outcomes in Dermatology. <i>Current Dermatology Reports</i> , 2015, 4, 15-19.	1.1	3
142	Comparing cutaneous research funded by the US National Institutes of Health (NIH) with the US skin disease burden. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 383-391.e1.	0.6	30
143	Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 968-977.e2.	0.6	43
144	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015, 373, 1318-1328.	13.9	656

#	ARTICLE	IF	CITATIONS
145	Effectiveness of a novel interactive health care education tool on clinical outcomes and quality of life in acne patients: A randomized controlled pilot study. <i>Journal of Dermatological Treatment</i> , 2015, 26, 435-439.	1.1	8
146	Response to: "œls tonsillectomy a therapeutic option for plaque-type psoriasis?" <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e155.	0.6	0
147	The global burden of disease associated with alopecia areata. <i>British Journal of Dermatology</i> , 2015, 172, 1424-1426.	1.4	10
148	Comparing the Effectiveness of Automated Online Counseling to Standard Web-Based Education on Improving Acne Knowledge: A Randomized Controlled Trial. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 55-60.	3.3	2
149	An Evidence-Based Review of the Mechanism of Action, Efficacy, and Safety of Biologic Therapies in the Treatment of Psoriasis and Psoriatic Arthritis. <i>Current Medicinal Chemistry</i> , 2015, 22, 1930-1942.	1.2	14
150	Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis. <i>Dermatology Online Journal</i> , 2015, 21, .	0.2	4
151	Diet and nutrition in psoriasis: analysis of the National Health and Nutrition Examination Survey (NHANES) in the United States. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 327-332.	1.3	23
152	Psoriasis and smoking: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2014, 170, 304-314.	1.4	199
153	Comparative Prevalence of Complementary and Alternative Medicine Use Among Outpatients in Dermatology and Primary Care Clinics. <i>JAMA Dermatology</i> , 2014, 150, 1363.	2.0	13
154	JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis. <i>Journal of Immunology Research</i> , 2014, 2014, 1-7.	0.9	102
155	Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. <i>Journal of Dermatological Treatment</i> , 2014, 25, 401-408.	1.1	59
156	Videos to influence: a systematic review of effectiveness of video-based education in modifying health behaviors. <i>Journal of Behavioral Medicine</i> , 2014, 37, 218-233.	1.1	246
157	Psoriasis and dyslipidemia: a population-based study analyzing the National Health and Nutrition Examination Survey (<scp>NHANES</scp>). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1109-1112.	1.3	33
158	Updates in Rosacea: Epidemiology, Risk Factors, and Management Strategies. <i>Current Dermatology Reports</i> , 2014, 3, 23-28.	1.1	8
159	Treatments for Nail Psoriasis: A Systematic Review by the GRAPPA Nail Psoriasis Work Group. <i>Journal of Rheumatology</i> , 2014, 41, 2306-2314.	1.0	25
160	Public perception of dermatologists and comparison with other medical specialties: Results from a national survey. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 875-881.	0.6	26
161	Antidrug antibodies in psoriasis: a systematic review. <i>British Journal of Dermatology</i> , 2014, 170, 261-273.	1.4	143
162	Psoriasis prevalence among adults in the United States. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 512-516.	0.6	650

#	ARTICLE	IF	CITATIONS
163	Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 665-669.	0.6	51
164	Psoriasis and Sexual Behavior in Men: Examination of the National Health and Nutrition Examination Survey (NHANES) in the United States. <i>Journal of Sexual Medicine</i> , 2014, 11, 401-410.	0.3	17
165	Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, 91-97.	1.6	18
166	Effects of Biologic Agents and Other Disease-Modifying Antirheumatic Drugs on Cardiovascular Outcomes in Psoriasis and Psoriatic Arthritis: A Systematic Review. <i>Current Pharmaceutical Design</i> , 2014, 20, 500-512.	0.9	41
167	Endothelial Dysfunction and the Effects of TNF Inhibitors on the Endothelium in Psoriasis and Psoriatic Arthritis: A Systematic Review. <i>Current Pharmaceutical Design</i> , 2014, 20, 513-528.	0.9	80
168	Association between psoriasis and viral infections in the United States: focusing on hepatitis B, hepatitis C and human immunodeficiency virus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1312-1316.	1.3	26
169	Psoriasis, electrocardiographic characteristics, and incidence of atrial fibrillation. <i>Archives of Dermatological Research</i> , 2013, 305, 891-897.	1.1	15
170	Crowdsourcing for data collection: a pilot study comparing patient-reported experiences and clinical trial data for the treatment of seborrheic dermatitis. <i>Skin Research and Technology</i> , 2013, 19, 55-57.	0.8	6
171	Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 654-662.	0.6	327
172	Psoriasis and the Risk of Diabetes Mellitus. <i>JAMA Dermatology</i> , 2013, 149, 84.	2.0	262
173	Psoriasis and Sexual Behavior in U.S. Women: An Epidemiologic Analysis Using the National Health and Nutrition Examination Survey (NHANES). <i>Journal of Sexual Medicine</i> , 2013, 10, 326-332.	0.3	14
174	Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 949-958.	1.3	56
175	The association between psoriasis and hypertension. <i>Journal of Hypertension</i> , 2013, 31, 433-443.	0.3	175
176	Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Observational Studies. <i>Journal of the American Heart Association</i> , 2013, 2, e000062.	1.6	324
177	Do TNF Inhibitors Reduce the Risk of Myocardial Infarction in Psoriasis Patients?. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2043.	3.8	22
178	Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States. <i>JAMA Dermatology</i> , 2013, 149, 1180.	2.0	327
179	The association between psoriasis and dyslipidaemia: a systematic review. <i>British Journal of Dermatology</i> , 2013, 168, 486-495.	1.4	130
180	Standardizing Training for Psoriasis Measures. <i>JAMA Dermatology</i> , 2013, 149, 577.	2.0	42

#	ARTICLE	IF	CITATIONS
181	Tele dermatology Operational Considerations, Challenges, and Benefits: The Referring Providers' Perspective. <i>Telemedicine Journal and E-Health</i> , 2012, 18, 580-584.	1.6	41
182	Exploring Priority Research Areas in Psoriasis and Psoriatic Arthritis from Dermatologists's™ Perspective: A Report from the GRAPPA 2011 Annual Meeting. <i>Journal of Rheumatology</i> , 2012, 39, 2204-2210.	1.0	3
183	Psoriasis Comorbidities: Results from the National Psoriasis Foundation Surveys 2003 to 2011. <i>Dermatology</i> , 2012, 225, 121-126.	0.9	77
184	Why Some Dermatologists Do Not Practice Store-and-Forward Tele dermatology. <i>Archives of Dermatology</i> , 2012, 148, 649-50.	1.7	18
185	Melanoma: Epidemiology, Diagnosis, Treatment, and Outcomes. <i>Dermatologic Clinics</i> , 2012, 30, 113-124.	1.0	58
186	A Review of Health Outcomes in Patients with Psoriasis. <i>Dermatologic Clinics</i> , 2012, 30, 61-72.	1.0	28
187	State of tele dermatology programs in the United States. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 939-944.	0.6	81
188	Power of crowdsourcing: Novel methods of data collection in psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 1273-1281.e9.	0.6	18
189	Harnessing the Power of Crowds. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 405-416.	3.3	25
190	Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy. <i>PLoS ONE</i> , 2012, 7, e33486.	1.1	92
191	Innovations in tele dermatology: direct patient's specialist care enabled by mobile technology. <i>Expert Review of Dermatology</i> , 2012, 7, 223-225.	0.3	0
192	Coronary Artery Disease in Patients With Psoriasis Referred for Coronary Angiography. <i>American Journal of Cardiology</i> , 2012, 109, 976-980.	0.7	90
193	Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003's 2011. <i>PLoS ONE</i> , 2012, 7, e52935.	1.1	235
194	Novel approach to utilizing electronic health records for dermatologic research: developing a multi-institutional federated data network for clinical and translational research in psoriasis and psoriatic arthritis. <i>Dermatology Online Journal</i> , 2012, 18, 2.	0.2	5
195	Angiogenesis and oxidative stress: Common mechanisms linking psoriasis with atherosclerosis. <i>Journal of Dermatological Science</i> , 2011, 63, 1-9.	1.0	140
196	Online video improves clinical outcomes in adults with atopic dermatitis: A randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 502-507.	0.6	89
197	Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. <i>British Journal of Dermatology</i> , 2011, 165, 1162-1168.	1.4	110
198	A tale of two plaques: convergent mechanisms of T's mediated inflammation in psoriasis and atherosclerosis. <i>Experimental Dermatology</i> , 2011, 20, 544-549.	1.4	114

#	ARTICLE	IF	CITATIONS
199	Effects of video-based, online education on behavioral and knowledge outcomes in sunscreen use: A randomized controlled trial. <i>Patient Education and Counseling</i> , 2011, 83, 273-277.	1.0	97
200	Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010. <i>PLoS ONE</i> , 2011, 6, e17520.	1.1	129
201	Psoriasis and Hypertension Severity: Results from a Case-Control Study. <i>PLoS ONE</i> , 2011, 6, e18227.	1.1	78
202	Practice Models and Challenges in Tele dermatology: A Study of Collective Experiences from Tele dermatologists. <i>PLoS ONE</i> , 2011, 6, e28687.	1.1	73
203	Portable video media for presenting informed consent and wound care instructions for skin biopsies: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2010, 163, 1014-1019.	1.4	47
204	Evaluation and Comparison of Store-and-Forward Tele dermatology Applications. <i>Telemedicine Journal and E-Health</i> , 2010, 16, 424-438.	1.6	29
205	Public Perception of SARS-CoV-2 Vaccines Among Psoriasis Patients in Social Media: Content, Sentiment, and Engagement Analysis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 0, , 247553032211100.	0.3	0
206	Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. <i>Journal of Dermatological Treatment</i> , 0, , 1-9.	1.1	1